Compare
AbbVie vs Arrowhead Pharmaceuticals (ABBV vs ARWR)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Arrowhead Pharmaceuticals (ARWR) +44.3%; so far this year the figures are +27.5% and -12.4%.
AbbVie is the larger company by market value, about 62.6 times the size of Arrowhead Pharmaceuticals.
Revenue grew +10.7% at ABBV and +16.8% at ARWR over the last year.
ABBV yields 2.38%. ARWR pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | ARWR | |
|---|---|---|
| Price | $291.31 | $58.16 |
| 1-day | +1.07% | +1.22% |
| YTD | +27.49% | -12.40% |
| 1 year | +34.39% | +44.28% |
| 3 years | +104.47% | +125.51% |
| Market cap | $514.9B | $8.2B |
| P/E | 50.1 | — |
| P/S | 7.80 | 12.27 |
| P/B | — | 17.65 |
| Revenue growth | +10.70% | +16.80% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | -47.8 |
| ROE % | — | -68.7 |
| Debt / equity | — | 0.00 |
| FCF yield % | 3.7 | -0.9 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 1.60 |
| RSI (14) | 59.7 | 39.6 |
| Technical rating |